From 1978-2000 I was a tenured faculty member at New York University in chemistry (biophysical and medicinal) neuroscience, and biological psychiatry focused in the area of GPCRs, especially CCK and dopamine, and sigma-receptors. In 2000 I left the University as I had an opportunity to co-found Achillion Pharmaceuticals, Inc. (ACHN). Since that time I have served multiple roles in startup companies in the biotechnology and biopharmaceuticals industry. Two of the companies of which I was involved with as founder (ACHN) and Marinus Pharmaceuticals, Inc. (Founder and COO) (MRNS) are now public. I also played a key role in early phase operations of other successful public companies. I am currently a founder and CSO off Epalex Pharmaceuticals, a company focused on novel treatments for neurological diseases, in particular epilepsy and migraine. My goals are to bring early to late-phase discovery compounds to development candidates which will become useful clinical agents in due course.I simultaneously serve as CSO of Metagreen, Inc., a company which is focused on the role of cannabinoids in pain and epilepsy. Metagreen is developing novel processes for cannabinoid purification under GMP which has been rate-limiting in bringing these valuable materials to market. Metagreen and Eplaex have joint preclinical research programs on the uses of cannabinoids in these and other indications.Specialties: Discovery Medicinal Chemistry, Biochemical Pharmacology, Neuropharmacology, Neurophysiology, Biophysical Chemistry (Proteins/Peptides)